DK2968483T3 - Subkutan indgivelse af adamts13 - Google Patents

Subkutan indgivelse af adamts13 Download PDF

Info

Publication number: DK2968483T3
Authority: DK; Denmark
Prior art keywords: subcutan; adamts13; submission; subcutan submission
Prior art date: 2013-03-15

Application number

DK14719469.0T

Other languages

English (en)

Inventor

Alexandra Nathalie Kopic

Werner Hoellriegl

Barbara Plaimauer

Hanspeter Rottensteiner

Eva-Maria Muchitsch

Original Assignee

Takeda Pharmaceuticals Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-03-13

Publication date

2022-02-14

2014-03-13 Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co

2022-02-14 Application granted granted Critical

2022-02-14 Publication of DK2968483T3 publication Critical patent/DK2968483T3/da

Links

102000043853 ADAMTS13 Human genes 0.000 title 1
108091005670 ADAMTS13 Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Enzymes And Modification Thereof (AREA)

DK14719469.0T 2013-03-15 2014-03-13 Subkutan indgivelse af adamts13 DK2968483T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361794659P	2013-03-15	2013-03-15
PCT/US2014/026747 WO2014151968A1 (en)	2013-03-15	2014-03-13	Subcutaneous administration of adamts13

Publications (1)

Publication Number	Publication Date
DK2968483T3 true DK2968483T3 (da)	2022-02-14

Family

ID=50549463

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14719469.0T DK2968483T3 (da)	2013-03-15	2014-03-13	Subkutan indgivelse af adamts13

Country Status (18)

Country	Link
US (4)	US9611467B2 (da)
EP (2)	EP3960196A1 (da)
JP (4)	JP6484216B2 (da)
KR (5)	KR102365936B1 (da)
CN (2)	CN105407912A (da)
AU (5)	AU2013203062C1 (da)
BR (1)	BR112015023542A8 (da)
CA (1)	CA2905058A1 (da)
DK (1)	DK2968483T3 (da)
EA (2)	EA034546B1 (da)
ES (1)	ES2906550T3 (da)
IL (3)	IL241305B (da)
MX (2)	MX380485B (da)
PL (1)	PL2968483T3 (da)
PT (1)	PT2968483T (da)
SG (3)	SG10202001227QA (da)
TW (4)	TWI740207B (da)
WO (1)	WO2014151968A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2013203062C1 (en) *	2013-03-15	2018-06-28	Takeda Pharmaceutical Company Limited	Subcutaneous administration of adamts13
GB201510870D0 (en) *	2015-05-26	2015-08-05	Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh	Treatment of infarction
EA201990373A1 (ru)	2016-08-04	2019-07-31	Баксалта Инкорпорэйтед	Применение adamts13 для лечения, уменьшения интенсивности и/или предупреждения вазоокклюзивного криза при серповидноклеточной анемии, остром повреждении легкого и/или остром респираторном дистресс-синдроме
WO2020214033A1 (en) *	2019-04-17	2020-10-22	Erasmus University Medical Center Rotterdam	Papain-like cysteine peptidase medicaments and uses thereof
EP4037704B1 (en)	2019-10-04	2025-12-03	The Children's Medical Center Corporation	Adamts13 treatment to enhance graft survival
AU2021248679A1 (en)	2020-04-02	2022-10-27	Takeda Pharmaceutical Company Limited	ADAMTS13 variant, compositions, and uses thereof
EP4153215A1 (en) *	2020-05-22	2023-03-29	Takeda Pharmaceutical Company Limited	Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease
WO2021242092A1 (en) *	2020-05-25	2021-12-02	Sanquin Innovatie B.V.	Adamts13 protein variants and uses thereof
US20230405096A1 (en) *	2020-11-18	2023-12-21	Green Cross Corporation	Adamts13 variant having increased escaping rate or activity against autoantibody
GB202102208D0 (en) *	2021-02-17	2021-03-31	Univ Manchester	Adamts13 variant
KR20240112755A (ko) *	2023-01-11	2024-07-19	주식회사 녹십자	혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물
CN120826509A (zh)	2023-04-25	2025-10-21	住友电气工业株式会社	帘线-橡胶复合体、帘线-橡胶复合体的制造方法、轮胎

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL113010A (en)	1994-03-31	1999-10-28	Pharmacia & Upjohn Ab	Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6926894B2 (en)	2000-11-22	2005-08-09	Baxter Aktiengesellschaft	Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
AU2002336367A1 (en)	2001-08-16	2003-03-03	The Regents Of The University Of Michigan	Adamts13 genes and proteins and variants, and uses thereof
US7763430B2 (en) *	2003-04-22	2010-07-27	Baxter International Inc.	Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
AU2006257073B2 (en) *	2005-06-17	2011-08-04	Children's Medical Center Corporation	ADAMTS13-comprising compositions having thrombolytic activity
JP2009539757A (ja) *	2006-06-16	2009-11-19	バクスター・インターナショナル・インコーポレイテッド	血栓溶解活性を有するａｄａｍｔｓ１３含有組成物
AU2009246603B8 (en) *	2008-05-12	2015-08-13	Children's Medical Center Corporation	von Willebrand Factor (VWF) inhibitors for treatment or prevention of infarction
WO2011020866A2 (en) *	2009-08-20	2011-02-24	Csl Behring Gmbh	Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
KR20210054598A (ko) *	2009-09-21	2021-05-13	다케다 야쿠힌 고교 가부시키가이샤	안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
PT3626736T (pt) *	2010-07-08	2025-08-11	Takeda Pharmaceuticals Co	Método de produção de fvw recombinante de elevado peso molecular na cultura celular
AU2013203062C1 (en)	2013-03-15	2018-06-28	Takeda Pharmaceutical Company Limited	Subcutaneous administration of adamts13

2013
- 2013-04-09 AU AU2013203062A patent/AU2013203062C1/en active Active
2014
- 2014-03-13 MX MX2015012783A patent/MX380485B/es unknown
- 2014-03-13 EA EA201591758A patent/EA034546B1/ru not_active IP Right Cessation
- 2014-03-13 KR KR1020217004442A patent/KR102365936B1/ko active Active
- 2014-03-13 KR KR1020197005635A patent/KR102102087B1/ko active Active
- 2014-03-13 CN CN201480027202.3A patent/CN105407912A/zh active Pending
- 2014-03-13 JP JP2016502232A patent/JP6484216B2/ja active Active
- 2014-03-13 BR BR112015023542A patent/BR112015023542A8/pt not_active Application Discontinuation
- 2014-03-13 DK DK14719469.0T patent/DK2968483T3/da active
- 2014-03-13 CA CA2905058A patent/CA2905058A1/en active Pending
- 2014-03-13 SG SG10202001227QA patent/SG10202001227QA/en unknown
- 2014-03-13 WO PCT/US2014/026747 patent/WO2014151968A1/en not_active Ceased
- 2014-03-13 KR KR1020227005350A patent/KR102513872B1/ko active Active
- 2014-03-13 US US14/210,167 patent/US9611467B2/en active Active
- 2014-03-13 EP EP21203692.5A patent/EP3960196A1/en active Pending
- 2014-03-13 ES ES14719469T patent/ES2906550T3/es active Active
- 2014-03-13 PL PL14719469T patent/PL2968483T3/pl unknown
- 2014-03-13 SG SG10201707074TA patent/SG10201707074TA/en unknown
- 2014-03-13 SG SG11201507271QA patent/SG11201507271QA/en unknown
- 2014-03-13 EP EP14719469.0A patent/EP2968483B1/en active Active
- 2014-03-13 KR KR1020157028432A patent/KR20160016756A/ko not_active Ceased
- 2014-03-13 EA EA201992832A patent/EA201992832A1/ru unknown
- 2014-03-13 CN CN202111631652.1A patent/CN114259558A/zh active Pending
- 2014-03-13 KR KR1020207010406A patent/KR102218489B1/ko active Active
- 2014-03-13 PT PT147194690T patent/PT2968483T/pt unknown
- 2014-03-14 TW TW108133433A patent/TWI740207B/zh active
- 2014-03-14 TW TW103109832A patent/TWI690326B/zh active
- 2014-03-14 TW TW111144983A patent/TW202313664A/zh unknown
- 2014-03-14 TW TW110108163A patent/TWI786563B/zh active
2015
- 2015-09-08 IL IL241305A patent/IL241305B/en active IP Right Grant
- 2015-09-14 MX MX2021002513A patent/MX2021002513A/es unknown
2016
- 2016-09-22 AU AU2016231547A patent/AU2016231547B2/en active Active
2017
- 2017-02-22 US US15/439,154 patent/US10413600B2/en active Active
2018
- 2018-05-24 AU AU2018203665A patent/AU2018203665B2/en active Active
2019
- 2019-02-15 JP JP2019025097A patent/JP6998333B2/ja active Active
- 2019-09-11 US US16/567,048 patent/US11185575B2/en active Active
2020
- 2020-03-17 IL IL273365A patent/IL273365B/en unknown
- 2020-04-23 AU AU2020202738A patent/AU2020202738B2/en active Active
2021
- 2021-11-12 US US17/525,759 patent/US11779635B2/en active Active
- 2021-12-20 JP JP2021205839A patent/JP7238088B2/ja active Active
2022
- 2022-02-09 IL IL290486A patent/IL290486B2/en unknown
- 2022-08-05 AU AU2022211908A patent/AU2022211908B2/en active Active
2023
- 2023-03-01 JP JP2023030589A patent/JP2023071821A/ja active Pending

Also Published As

Publication number	Publication date
EP2968483A1 (en)	2016-01-20
US9611467B2 (en)	2017-04-04
AU2022211908A1 (en)	2022-09-01
CN114259558A (zh)	2022-04-01
JP2022027991A (ja)	2022-02-14
AU2013203062C1 (en)	2018-06-28
EA201591758A1 (ru)	2016-03-31
MX380485B (es)	2025-03-12
KR20220027266A (ko)	2022-03-07
US11779635B2 (en)	2023-10-10
IL273365B (en)	2022-05-01
SG11201507271QA (en)	2015-10-29
US11185575B2 (en)	2021-11-30
JP2016517421A (ja)	2016-06-16
US20140271611A1 (en)	2014-09-18
EA201591758A8 (ru)	2017-03-31
US20220080032A1 (en)	2022-03-17
TWI690326B (zh)	2020-04-11
JP2019142850A (ja)	2019-08-29
NZ751610A (en)	2020-11-27
TWI740207B (zh)	2021-09-21
KR20190022926A (ko)	2019-03-06
KR102365936B1 (ko)	2022-02-23
SG10202001227QA (en)	2020-03-30
CA2905058A1 (en)	2014-09-25
AU2020202738A1 (en)	2020-05-14
US20200101144A1 (en)	2020-04-02
JP6484216B2 (ja)	2019-03-13
EP3960196A1 (en)	2022-03-02
WO2014151968A1 (en)	2014-09-25
JP6998333B2 (ja)	2022-02-10
EP2968483B1 (en)	2021-12-01
SG10201707074TA (en)	2017-10-30
KR102102087B1 (ko)	2020-04-20
BR112015023542A8 (pt)	2019-12-03
TW202017591A (zh)	2020-05-16
JP2023071821A (ja)	2023-05-23
EA034546B1 (ru)	2020-02-19
TWI786563B (zh)	2022-12-11
AU2016231547B2 (en)	2018-03-15
MX2021002513A (es)	2021-04-28
BR112015023542A2 (pt)	2017-07-18
KR102513872B1 (ko)	2023-03-27
PL2968483T3 (pl)	2022-04-04
AU2020202738B2 (en)	2022-06-09
TW201513881A (zh)	2015-04-16
AU2018203665B2 (en)	2020-01-30
AU2013203062A1 (en)	2014-10-02
PT2968483T (pt)	2022-02-23
KR20160016756A (ko)	2016-02-15
AU2018203665A1 (en)	2018-06-14
KR20210021107A (ko)	2021-02-24
IL241305B (en)	2020-04-30
US20170224785A1 (en)	2017-08-10
IL273365A (en)	2020-05-31
HK1220131A1 (zh)	2017-04-28
AU2022211908B2 (en)	2023-11-30
CN105407912A (zh)	2016-03-16
ES2906550T3 (es)	2022-04-19
KR102218489B1 (ko)	2021-02-22
IL241305A0 (en)	2015-11-30
NZ749570A (en)	2020-11-27
AU2013203062B2 (en)	2016-06-23
TW202138003A (zh)	2021-10-16
MX2015012783A (es)	2016-04-28
NZ712440A (en)	2020-11-27
TW202313664A (zh)	2023-04-01
JP7238088B2 (ja)	2023-03-13
IL290486A (en)	2022-04-01
AU2016231547A1 (en)	2016-10-06
WO2014151968A8 (en)	2015-10-15
IL290486B1 (en)	2023-04-01
KR20200041394A (ko)	2020-04-21
EA201992832A1 (ru)	2020-05-31
IL290486B2 (en)	2023-08-01
US10413600B2 (en)	2019-09-17

Publication	Publication Date	Title
IL269227B (en)	2021-01-31	Solid forms of treprostinil
DK3087183T3 (da)	2020-09-14	Modulation af angiopoietin-3-lignende ekspression
DK2968208T3 (da)	2022-08-22	Behandling af kataplexi
DK3882346T3 (da)	2025-12-22	Hidtil ukendte metalloproteaser
DK3342773T3 (da)	2021-02-15	Syk-hæmmere
DK3613453T3 (da)	2021-10-11	Fordamper
DK2961388T3 (da)	2019-07-08	Kombinationer af lægemidler
DK2970954T3 (da)	2019-01-02	Modifikation af polypeptider
DK2981255T3 (da)	2022-11-14	Terapeutiske anvendelser af empagliflozin
DK3079750T3 (da)	2020-07-13	Udskyllelige katetre
PT2953948T (pt)	2017-12-12	Antagonistas de integrina fluorada
DK3077047T3 (da)	2019-07-15	Aramcholsalte
DK3052081T3 (da)	2021-01-18	Pastil
DK2965026T3 (da)	2019-10-28	Generering af slushice
DK3060460T3 (da)	2021-04-19	Saddel
HRP20171890T1 (hr)	2018-01-12	Supstituirani imidazopiridazini
DK3027598T3 (da)	2017-05-22	Oxoquinazolinyl-butanamidderivater
DK2956698T3 (da)	2021-02-08	Bindestrimler
DK3063264T3 (da)	2020-01-13	Tørring af mikroorganismer
DK3620198T3 (da)	2021-04-12	Udskyllelige katetre
EP2945942A4 (en)	2016-08-03	Voriconazole IMMUNOASSAY
DK2946640T3 (da)	2017-11-20	Langmuir-probe
DE102013106534B8 (de)	2015-06-18	Chromatographiepipettenspitze
UA27558S (uk)	2014-08-11	Лінза
DK2822301T3 (da)	2019-07-01	Bestemmelse af individuelle HRTF